Angelman Syndrome


To learn more about Angelman syndrome, connect with others in the community, and find resources to help you navigate a diagnosis, please visit the following links.

Learn more about clinical trials: STARS and ELARA

Frequently Asked Questions

Ovid Therapeutics is currently developing a potential treatment option for Angelman syndrome. To learn more about our clinical trials, please visit our website.

For more information about active clinical studies, please visit and register with the Angelman Syndrome Foundation and the Angelman Syndrome Registry Project, or visit

To determine if your loved one may be eligible for participation in one of Ovid’s clinical trials, please visit our website or contact us at

No. The investigational medicine and care required by Ovid’s studies will be provided at no expense. You will also be reimbursed for travel-related expenses.

Ovid is committed to developing potential therapies for those with Angelman syndrome and other neurological conditions. We look forward to providing updates to the community about our Angelman syndrome program and future clinical studies. Visit our website and follow our social channels for the latest news.

Half of individuals with Angelman syndrome are originally misdiagnosed.1 In most cases, a blood test identifies whether the UBE3A gene is functioning properly, however 15-20% of individuals require observation by an experienced clinician who is familiar with Angelman syndrome.1 To find a clinician in your area, contact the ASF.

Contact Us

“Biotech innovation means creating a collaborative and compliant standard of face-to-face interaction with patients. This thinking is not patient-centric, it is human-centric.”

Luke Rosen,
Associate Director of Patient Engagement, Ovid Therapeutics

For clinical and scientific questions about Ovid’s experimental therapies, please contact


1. ASF Diagnosis. Accessed June 14, 2018.